World's Best Scientists 2026 revealed!
Antoine Italiano

Antoine Italiano

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Medicine 83 15423 14508 500 474 458 32681

Antoine Italiano publications per year

The chart shows the history of publications by Antoine Italiano between 2004 and 2026, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Antoine Italiano published across 23 years, from 2004 to 2026, averaging 50.9 papers a year. Output peaked at 344 publications in 2023. 114 of the 1,170 publications appeared in the last two years.

No. of publications
100 200 300
Bar chart. Horizontal axis: year, 2004 to 2026. Vertical axis: number of publications, 0 to 344. Peak 344 publications in 2023. 2004: 1 publication 2005: 4 publications 2006: 0 publications 2007: 2 publications 2008: 7 publications 2009: 7 publications 2010: 12 publications 2011: 11 publications 2012: 26 publications 2013: 19 publications 2014: 29 publications 2015: 40 publications 2016: 31 publications 2017: 47 publications 2018: 55 publications 2019: 53 publications 2020: 66 publications 2021: 54 publications 2022: 102 publications 2023: 344 publications 2024: 146 publications 2025: 103 publications 2026: 11 publications
2004 2026

1,170 publications in total across all disciplines

View publications per year as a table
Antoine Italiano: publications per year, 2004 to 2026
Year Publications
2004 1
2005 4
2006 0
2007 2
2008 7
2009 7
2010 12
2011 11
2012 26
2013 19
2014 29
2015 40
2016 31
2017 47
2018 55
2019 53
2020 66
2021 54
2022 102
2023 344
2024 146
2025 103
2026 11
Total 1,170
Download as CSV

Antoine Italiano publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Antoine Italiano sits on this spectrum.

No. of scientists
200 400 600 800
Bar chart with 86 bars. Horizontal axis: publications, 101–120 to 1,796+. Vertical axis: number of scientists, 0 to 922. Most scientists, 922, have 341–360 publications. The last bar groups every scientist with 1,796 publications or more. The highlighted bar, 441–460 publications, is where this scientist sits. 101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101–120 publications 1,796+

This scientist: 458 publications — 50th percentile

50% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

View publications distribution as a table
Number of Medicine scientists by publication count, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
Publications Scientists This scientist
101–120 5
121–140 26
141–160 73
161–180 155
181–200 230
201–220 363
221–240 487
241–260 545
261–280 722
281–300 768
301–320 834
321–340 895
341–360 922
361–380 838
381–400 861
401–420 918
421–440 806
441–460 771 458
461–480 751
481–500 713
501–520 617
521–540 610
541–560 537
561–580 504
581–600 509
601–620 396
621–640 386
641–660 371
661–680 340
681–700 336
701–720 307
721–740 259
741–760 230
761–780 228
781–800 217
801–820 204
821–840 186
841–860 177
861–880 155
881–900 139
901–920 145
921–940 116
941–960 133
961–980 91
981–1,000 96
1,001–1,020 77
1,021–1,040 70
1,041–1,060 63
1,061–1,080 77
1,081–1,100 49
1,101–1,120 54
1,121–1,140 49
1,141–1,160 51
1,161–1,180 35
1,181–1,200 39
1,201–1,220 26
1,221–1,240 37
1,241–1,260 36
1,261–1,280 27
1,281–1,300 32
1,301–1,320 28
1,321–1,340 17
1,341–1,360 30
1,361–1,380 28
1,381–1,400 17
1,401–1,420 21
1,421–1,440 15
1,441–1,460 12
1,461–1,480 12
1,481–1,500 18
1,501–1,520 14
1,521–1,540 17
1,541–1,560 15
1,561–1,580 6
1,581–1,600 2
1,601–1,620 12
1,621–1,640 11
1,641–1,660 8
1,661–1,680 5
1,681–1,700 5
1,701–1,720 10
1,721–1,740 12
1,741–1,760 14
1,761–1,780 6
1,781–1,795 5
1,796+ 100
Download as CSV

Antoine Italiano D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Antoine Italiano sits on this spectrum.

No. of scientists
250 500 750 1,000
Bar chart with 75 bars. Horizontal axis: D-Index, 70–71 to 217+. Vertical axis: number of scientists, 0 to 1,027. Most scientists, 1,027, have 82–83 D-Index. The last bar groups every scientist with 217 D-Index or more. The highlighted bar, 82–83 D-Index, is where this scientist sits. 70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70–71 D-Index 217+

This scientist: 83 D-Index — 24th percentile

24% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

View D-Index distribution as a table
Number of Medicine scientists by D-index, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
D-Index Scientists This scientist
70–71 226
72–73 391
74–75 574
76–77 730
78–79 891
80–81 972
82–83 1,027 83
84–85 1,003
86–87 960
88–89 970
90–91 922
92–93 839
94–95 808
96–97 779
98–99 668
100–101 611
102–103 630
104–105 513
106–107 541
108–109 445
110–111 429
112–113 399
114–115 393
116–117 318
118–119 302
120–121 287
122–123 255
124–125 256
126–127 252
128–129 230
130–131 179
132–133 168
134–135 163
136–137 159
138–139 134
140–141 134
142–143 118
144–145 109
146–147 106
148–149 74
150–151 79
152–153 80
154–155 87
156–157 57
158–159 74
160–161 69
162–163 60
164–165 53
166–167 39
168–169 42
170–171 32
172–173 39
174–175 40
176–177 28
178–179 19
180–181 23
182–183 31
184–185 18
186–187 20
188–189 22
190–191 13
192–193 21
194–195 12
196–197 12
198–199 14
200–201 15
202–203 13
204–205 10
206–207 8
208–209 4
210–211 12
212–213 11
214–215 10
216 4
217+ 98
Download as CSV

Overview

Antoine Italiano is affiliated with the University of Bordeaux in France. Their research spans across multiple fields including Medicine and Biochemistry, Genetics and Molecular Biology, with a strong emphasis on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Cancer Research, and Immunology.

The main topics covered in their research include:

  • Sarcoma Diagnosis and Treatment
  • Cancer Immunotherapy and Biomarkers
  • Cancer Genomics and Diagnostics
  • Lung Cancer Treatments and Mutations
  • CAR-T cell therapy research
  • Colorectal Cancer Treatments and Studies
  • Vascular Tumors and Angiosarcomas

Antoine Italiano has contributed to a range of recent publications, some of which are:

  • Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study (2020), published in The Lancet Oncology
  • B cells are associated with survival and immunotherapy response in sarcoma (2020), published in Nature
  • Sotorasib for Lung Cancers with KRAS p.G12C Mutation (2021), published in New England Journal of Medicine
  • B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome (2022), published in Nature Reviews Clinical Oncology
  • ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group (2022), published in Annals of Oncology

The scientist frequently publishes in several notable venues, including:

  • Annals of Oncology (79 publications)
  • Journal of Clinical Oncology (79 publications)
  • Cancer Research (74 publications)
  • Clinical Cancer Research (19 publications)
  • European Journal of Cancer (19 publications)

Collaborative work is a significant aspect of Antoine Italiano's research output. Frequent co-authors include:

  • Jean-Yves Blay (103 joint works)
  • Alban Bessede (65 joint works)
  • Maud Toulmonde (62 joint works)
  • Sophie Cousin (61 joint works)
  • François Le Loarer (61 joint works)

Best Publications

  • Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

    David M. Hyman;Igor Puzanov;Vivek Subbiah;Jason E. Faris

  • B cells are associated with survival and immunotherapy response in sarcoma.

    Florent Petitprez;Aurélien de Reyniès;Emily Z. Keung;Tom Wei Wu Chen

  • Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy

    Carola H. Ries;Michael A. Cannarile;Sabine Hoves;Jörg Benz

  • Sotorasib for Lung Cancers with KRAS p.G12C Mutation.

    Ferdinandos Skoulidis;Bob T. Li;Grace K. Dy;Timothy J. Price

  • Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study.

    Hyun Cheol Chung;Willeke Ros;Jean Pierre Delord;Ruth Perets

  • Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

    Patrick Schöffski;Sant Chawla;Robert G. Maki;Antoine Italiano

  • Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study.

    Isabelle Ray-Coquard;Jean-Yves Blay;Antoine Italiano;Axel Le Cesne

  • Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study

    Antoine Italiano;Jean-Charles Soria;Maud Toulmonde;Jean-Marie Michot

  • Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression

    Lucile Vanhersecke;Maxime Brunet;Jean-Philippe Guégan;Christophe Rey

  • CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study

    Philippe A Cassier;Antoine Italiano;Carlos A Gomez-Roca;Christophe Le Tourneau

  • Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.

    Vivek Subbiah;Ulrik Lassen;Elena Élez;Antoine Italiano

  • Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial.

    Maud Toulmonde;Nicolas Penel;Julien Adam;Julien Adam;Christine Chevreau

  • Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.

    Susan M. Domchek;Sophie Postel-Vinay;Sophie Postel-Vinay;Sophie Postel-Vinay;Seock Ah Im;Yeon Hee Park

  • Trends in survival for patients with metastatic soft-tissue sarcoma†

    Antoine Italiano;Simone Mathoulin-Pelissier;Axel Le Cesne;Philippe Terrier

  • Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study.

    Florence Duffaud;Olivier Mir;Pascaline Boudou-Rouquette;Sophie Piperno-Neumann

  • Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study.

    Mrinal Gounder;Patrick Schöffski;Robin L. Jones;Mark Agulnik

  • Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial

    Olivier Mir;Thomas Brodowicz;Antoine Italiano;Jennifer Wallet

  • Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis

    Philippe A. Cassier;Hans Gelderblom;Silvia Stacchiotti;David Thomas

Frequent Co-Authors

Jean-Yves Blay
Jean-Yves Blay Claude Bernard University Lyon 1
Christine Chevreau
Christine Chevreau DuPont (United States)
Axel Le Cesne
Axel Le Cesne Institut Gustave Roussy
François Bertucci
François Bertucci Aix-Marseille University
Isabelle Ray-Coquard
Isabelle Ray-Coquard Claude Bernard University Lyon 1
Jean-Michel Coindre
Jean-Michel Coindre University of Bordeaux
Robert G. Maki
Robert G. Maki University of Pennsylvania
Hans Gelderblom
Hans Gelderblom Leiden University Medical Center
Silvia Stacchiotti
Silvia Stacchiotti University of Milan
Alessandro Gronchi
Alessandro Gronchi University of Milan

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative and supplementary healthcare degrees can broaden your career options within the medical field. Online learning makes it easier than ever to access top-rated programs wherever you are based.

For those interested in advanced pharmacy roles, a 3 year online pharmd program is a flexible pathway, offering rigorous training from home for those pursuing pharmacy licensure. Alternatively, if you are passionate about health data and technology, an online mhi (Master’s in Health Information Management) opens doors to leadership in medical records and informatics.

There are also high-demand, entry-level roles available. Those seeking quick certification can consider the cheapest medical billing and coding online courses to build skills in administrative healthcare operations.

For those who want to advance nursing careers without commuting or relocating, many colleges now offer affordable online fnp programs for becoming a Family Nurse Practitioner.

Whether you are changing focus or seeking advancement, these online options offer flexibility, affordability, and wide-ranging career potential in healthcare.

Best Scientists Citing Antoine Italiano

Trending Scientists

Recently Published Articles